4.1 Article

Detection of a novel frameshift mutation and regions with homozygosis within ARHGEF28 gene in familial amyotrophic lateral sclerosis

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/21678421.2012.758288

关键词

Rho guanine nucleotide exchange factor; ARHGEF28; ALS; mutation; homozygosity; protein aggregates; neurofilament

资金

  1. Canadian Institute of Health Research (CIHR)
  2. ALS Society of Canada

向作者/读者索取更多资源

Rho guanine nucleotide exchange factor (RGNEF) is a novel NFL mRNA destabilizing factor that forms neuronal cytoplasmic inclusions in spinal motor neurons in both sporadic (SALS) and familial (FALS) ALS patients. Given the observation of genetic mutations in a number of mRNA binding proteins associated with ALS, including TDP-43, FUS/TLS and mtSOD1, we analysed the ARHGEF28 gene (approx. 316 kb) that encodes for RGNEF in FALS cases to determine if mutations were present. We performed genomic sequencing, copy number variation analysis using TaqMan real-time PCR and spinal motor neuron immunohistochemistry using a novel RGNEF antibody. In this limited sample of FALS cases (n = 7) we identified a heterozygous mutation that is predicted to generate a premature truncated gene product. We also observed extensive regions of homozygosity in the ARHGEF28 gene in two FALS patients. In conclusion, our findings of genetic alterations in the ARHGEF28 gene in cases of FALS suggest that a more comprehensive genetic analysis would be warranted.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Pathology

How reliable are polygenic risk scores for risk prediction in patients with heart disease?

Erin O. Jacob, Robert A. Hegele

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2023)

Article Pharmacology & Pharmacy

The longitudinal triglyceride phenotype in heterozygotes with LPL pathogenic variants

Shehan D. Perera, Jian Wang, Adam D. McIntyre, Jacqueline S. Dron, Robert A. Hegele, Cert Endo

Summary: In this study, the longitudinal triglyceride (TG) phenotype of individuals with heterozygous pathogenic LPL variants was evaluated. The results showed that TG levels varied widely among patients and within the same patient. Most patients exhibited mild-to-moderate and severe hypertriglyceridemia (HTG), and the severity likely depended on secondary factors.

JOURNAL OF CLINICAL LIPIDOLOGY (2023)

Editorial Material Cardiac & Cardiovascular Systems

'Keep on keeping on': persistence with lipid-lowering treatment in familial hypercholesterolaemia

Robert A. Hegele

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

The Impact of Low-Density Lipoprotein Equation Changes on Cholesterol Treatment in Canada

Pei Jun Zhao, Robert A. Hegele

Summary: The Canadian Society of Clinical Chemists has recommended adopting the more accurate Sampson/US NIH LDL-C equation for cardiovascular disease prevention. Based on the comparison of survey data, it is estimated that approximately 123,000 Canadians who are already taking cholesterol-lowering medications may need to intensify treatment due to the equation change.

CJC OPEN (2023)

Editorial Material Cardiac & Cardiovascular Systems

Apolipoprotein C-II: a new look at an old protein

Robert A. Hegele

EUROPEAN HEART JOURNAL (2023)

Review Cardiac & Cardiovascular Systems

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

Marina Cuchel, Frederick J. Raal, Robert A. Hegele, Khalid Al-Rasadi, Marcello Arca, Maurizio Averna, Eric Bruckert, Tomas Freiberger, Daniel Gaudet, Mariko Harada-Shiba, Lisa C. Hudgins, Meral Kayikcioglu, Luis Masana, Klaus G. Parhofer, Jeanine E. Roeters van Lennep, Raul D. Santos, Erik S. G. Stroes, Gerald F. Watts, Albert Wiegman, Jane K. Stock, Lale S. Tokgoezoglu, Alberico L. Catapano, Kausik K. Ray

Summary: This 2023 statement provides updated clinical guidance for the management of homozygous familial hypercholesterolaemia (HoFH), including criteria for diagnosis, genetic testing interpretation, and treatment recommendations. The statement emphasizes the importance of considering both phenotype and genotype in the diagnosis of HoFH, with a LDL-C level >10 mmol/L (>400 mg/dL) being indicative of the condition. Combination therapy targeting LDL-C, including the use of novel therapies like proprotein convertase subtilisin/kexin type 9 inhibitors, is recommended to achieve LDL-C goals and reduce the need for lipoprotein apheresis. To improve HoFH care globally, the statement recommends the implementation of national screening programs, education to increase awareness, and management guidelines adapted to local healthcare systems.

EUROPEAN HEART JOURNAL (2023)

Article Biochemistry & Molecular Biology

Genetic testing in monogenic early-onset atrial fibrillation

Brandon Chalazan, Emma Freeth, Arezoo Mohajeri, Krishnan Ramanathan, Matthew Bennett, Jagdeep Walia, Laura Halperin, Thomas Roston, Julieta Lazarte, Robert A. Hegele, Anna Lehman, Zachary Laksman

Summary: This study aims to determine the prevalence of likely pathogenic and pathogenic variants from AF genes in early-onset AF patients. The results suggest a potential clinical utility for offering different screening and treatment regimens in AF patients with a genetic defect.

EUROPEAN JOURNAL OF HUMAN GENETICS (2023)

Review Pharmacology & Pharmacy

Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors

Catherine M. Spagnuolo, Robert A. Hegele

Summary: Mild-to-moderate hypertriglyceridemia (HTG) is associated with atherosclerotic cardiovascular disease (ASCVD) and elevated triglyceride (TG) levels. Apolipoprotein C-III (apo C-III) inhibition is a promising treatment approach for reducing TG levels and ASCVD risk. Biologic agents like volanesorsen, olezarsen, and ARO-APOC3 significantly reduce apo C-III and TG levels, but further study is needed on their impact on cardiovascular outcomes.

EXPERT OPINION ON PHARMACOTHERAPY (2023)

Article Cardiac & Cardiovascular Systems

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

Gerald F. Watts, Samuel S. Gidding, Robert A. Hegele, Frederick J. Raal, Amy C. Sturm, Laney K. Jones, Mitchell N. Sarkies, Khalid Al-Rasadi, Dirk J. Blom, Magdalena Daccord, Sarah D. de Ferranti, Emanuela Folco, Peter Libby, Pedro Mata, Hapizah M. Nawawi, Uma Ramaswami, Kausik K. Ray, Claudia Stefanutti, Shizuya Yamashita, Jing Pang, Gilbert R. Thompson, Raul D. Santos

Summary: Familial hypercholesterolaemia (FH) is a preventable cause of premature coronary artery disease and death. This guidance article from the International Atherosclerosis Society provides a comprehensive overview of FH care that includes recommendations on the detection and management of patients with FH, as well as strategies to maximize implementation.

NATURE REVIEWS CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Genetic Identification of Homozygous Familial Hypercholesterolemia by Long-Read Sequencing Among Patients With Clinically Diagnosed Heterozygous Familial Hypercholesterolemia

Ahsen Chaudhry, Mark Trinder, Kristin Vesely, Lubomira Cermakova, Linda Jackson, Jian Wang, Robert A. Hegele, Liam R. Brunham

Summary: A study found that approximately 0.9% of patients clinically diagnosed with heterozygous familial hypercholesterolemia (HeFH) actually had homozygous familial hypercholesterolemia (HoFH) based on genetic diagnosis. These patients had higher levels of low-density lipoprotein cholesterol and a higher prevalence of premature cardiovascular disease.

CIRCULATION-GENOMIC AND PRECISION MEDICINE (2023)

Review Cardiac & Cardiovascular Systems

Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management

Iulia Iatan, G. B. John Mancini, Eunice Yeoh, Robert A. Hegele

Summary: Statins are important for reducing the risk of atherosclerotic cardiovascular disease, but they are underutilized due to concerns about side effects. Statin-associated muscle symptoms are a common cause of intolerance and discontinuation, leading to increased risk of adverse cardiovascular outcomes.

EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2023)

Review Endocrinology & Metabolism

Low cholesterol states: clinical implications and management

Praneet K. K. Gill, Robert A. A. Hegele

Summary: This article reviews the causes and consequences of hypocholesterolemia resulting from genetic and non-genetic factors, and discusses therapeutic strategies inspired by genetic hypocholesterolemia.

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2023)

Editorial Material Hematology

Academic-Industry Partnerships: Transparency, Potential Conflict of Interest, and Communicating State-of-the-Art Technologies

Ann Marie Schmidt, Mary G. Sorci-Thomas, Yabing Chen, Robert A. Hegele

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2023)

Editorial Material Cardiac & Cardiovascular Systems

Illuminating the full spectrum of APOE variation

Robert A. Hegele

ATHEROSCLEROSIS (2023)

Article Genetics & Heredity

Polygenic risk for triglyceride levels in the presence of a high impact rare variant

Shengjie Ying, Tracy Heung, Bhooma Thiruvahindrapuram, Worrawat Engchuan, Yue Yin, Christina Blagojevic, Zhaolei Zhang, Robert A. Hegele, Ryan K. C. Yuen, Anne S. Bassett

Summary: Elevated TG levels are modifiable risk factors for cardiovascular disease, and this study found that the TG-PRS, along with sex and BMI, were significant predictors of TG levels, especially in individuals with obesity. A combination of TG-PRS, sex, and BMI showed the greatest accuracy in predicting mild-moderate hypertriglyceridemia.

BMC MEDICAL GENOMICS (2023)

暂无数据